A new delivery device for benralizumab (autoinjector, pen-injector device) in the clinical practice of treating severe eosinophilic asthma: Conclusion of the Expert Council

The emergence of new means of administering genetically-engineered biological drugs, such as an autoinjector (pen injector device), can positively affect the organizational aspects of treating patients with severe eosinophilic asthma (SA) who need biological therapy.

The aim. To determine the place of a new delivery device for benralizumab (autoinjector, pen injector device) in the clinical practice of treating eosinophilic SA.

Results. The expert council considered the results of the latest clinical studies and real practice data on the use of genetically-engineered biological drugs in the form of an autoinjector. The experts discussed the safety and efficacy of this delivery device and recommended considering the possibility of switching eosinophilic SA patients to self-administration of genetically-engineered biological drugs (autoinjector form) at home. This treatment tactic is especially relevant in the current epidemiological situation since it will reduce the risks of infection compared to planned medical care in inpatient or outpatient treatment settings and reduce the burden for healthcare workers.

Conclusion. The practice of switching eosinophilic SA patients to self-administration of biologics in the form of an autoinjector (pen injector device) can improve the adherence to biological therapy and quality of life of this group of patients.

1. Avdeev S.N., Nenasheva N.M., Zhudenkov K.V. et al. [Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in Russian Federation]. Pul’monologiya. 2018; 28 (3): 341-358. DOI: 10.18093/0869-0189-2018-28-3-341-358 (in Russian).

2. Nenasheva N.M. [Biological therapy of asthma: present and future]. Consilium Medicum. 2016; 18 (11): 30-38.DOI:10.26442/2075-1753_2016.11.30-38 (in Russian).

3. Nenasheva N.M., Kurbacheva O.M., Avdeev S.N. et al. [Practical recommendations for choosing an immunobiological preparation for the treatment of severe bronchial asthma of T2-endotype]. Pul’monologiya. 2020; 30 (2): 227-244. DOI: 10.18093/0869-0189-2020-30-2-227-244 (in Russian).

4. van den Bemt B.J.F., Gettings L., Domahska B. et al. A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv. 2019; 26 (1): 384-392. DOI: 10.1080/10717544.2019.1587043.

5. Cross M.J., March L.M., Lapsley H.M. et al. Patient self-efficacy and health locus of control: relationships with health status and arthritis-related expenditure. Rheumatology (Oxford). 2006; 45 (1): 92-96. DOI: 10.1093/rheumatology/kei114.

6. Keininger D, Coteur G. Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ). Health Qual. Life Outcomes. 2011; 9: 2. DOI: 10.1186/1477-7525-9-2.

7. Pham T.H., Damera G., Newbold P., Ranade K. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir. Med. 2016; 111: 21-29. DOI: 10.1016/j.rmed.2016.01.003.

8. Kolbeck R., Kozhich A., Koike M. et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell mediated cytotoxicity function. J. Allergy Clin. Immunol. 2010; 125 (6): 1344— 1353.e2. DOI: 10.1016/j.jaci.2010.04.004.

9. FitzGerald J.M., Bleecker E.R., Nair P. et al. Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2128-2141. DOI: 10.1016/S0140-6736(16)31322-8.

10. Goldman M., Hirsch I., Zangrilli J.G. et al. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the phase III SIROCCO and CALIMA studies. Curr. Med. Res. Opin. 2017; 33 (9): 1605-1613. DOI: 10.1080/03007995.2017.1347091.

11. Nair P., Wenzel S., Rabe K.F. et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N. Engl. J. Med. 2017; 376 (25): 2448-2458. DOI: 10.1056/NEJMoa1703501.

12. Bleecker E.R., FitzGerald J.M., Chanez P. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting |32-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2115-2127. DOI: 10.1016/S0140-6736(16)31324-1.

13. Ferguson G.T., Cole J., Aurivillius M. et al. Single-use autoinjector functionality and reliability for at-home administration of benralizumab for patients with severe asthma: GRECO trial results. J. Asth -ma Allergy. 2019; 12: 363-373. DOI: 10.2147/JAA.S224266.

14. Martin U.J., Fuhr R., Forte P. et al. Comparison of autoinjector with accessorized prefilled syringe for benralizumab pharmacokinetic exposure: AMES trial results. J. Asthma. 2019; 58 (1): 93-101. DOI: 10.1080/02770903.2019.1663428.